Pharmacological suppression of the SHH signaling pathway led to dramatic inhibition of cell proliferation in vitro and tumor growth in vivo, proposing that HPI can be an effective and attractive molecular target therapy for human intrahepatic CCC. This evidence concerns the gene SHH and neoplasm.